Royalty Pharma plc(RPRX)Earnings, Financials & Key Ratios

RPRX•NASDAQ

$50.69

$21.72B mkt cap·28.2× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryRoyalty and IP Monetization Vehicles

AboutRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Show more

Revenue$2.38B+5.1%
EBITDA$1.56B+0.5%
Net Income$771M-10.2%
EPS (Diluted)1.80+24.1%
Gross Margin100%
EBITDA Margin65.74%-4.4%
Operating Margin65.58%+14.8%
Net Margin32.42%-14.6%
ROE7.69%-8.6%
ROIC6.67%+12.7%
Debt/Equity0.92+25.2%
Interest Coverage5.30-23.1%

Analysis→Technical→

RPRX Key Insights

Royalty Pharma plc (RPRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓FCF machine: 104.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 5.8% through buybacks
✓Healthy 5Y average net margin of 29.5%
✓Trading near 52-week high

✗Weaknesses

✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

RPRX Price & Volume

Royalty Pharma plc (RPRX) stock price & volume — 10-year historical chart

Loading chart...

RPRX Growth Metrics

Royalty Pharma plc (RPRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years2.3%

3 Years2.06%

TTM7.82%

Profit CAGR

10 Years-

5 Years-4.59%

3 Years162.07%

TTM-24.25%

EPS CAGR

10 Years-

5 Years7.06%

3 Years162.07%

TTM-42.86%

Return on Capital

10 Years10.2%

5 Years7.27%

3 Years8.61%

Last Year8.68%

RPRX Recent Earnings

Royalty Pharma plc (RPRX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (25%)

Q2 2026Latest

May 6, 2026

EPS

$0.53

Est $1.22

-56.6%

Revenue

$925M

Est $882M

+4.9%

Q1 2026

Feb 11, 2026

EPS

$1.46

Est $1.29

+13.2%

Revenue

$874M

Est $807M

+8.3%

Q4 2025

Nov 5, 2025

EPS

$1.17

Est $0.99

+17.7%

Revenue

$609M

Est $717M

-15.1%

Q3 2025

Aug 6, 2025

EPS

$1.14

Est $1.03

+10.7%

Revenue

$579M

Est $673M

-14.0%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 6, 2026	$0.53vs $1.22-56.6%	$925Mvs $882M+4.9%
Q1 2026	Feb 11, 2026	$1.46vs $1.29+13.2%	$874Mvs $807M+8.3%
Q4 2025	Nov 5, 2025	$1.17vs $0.99+17.7%	$609Mvs $717M-15.1%
Q3 2025	Aug 6, 2025	$1.14vs $1.03+10.7%	$579Mvs $673M-14.0%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
RCUSArcus Biosciences, Inc.Direct Competitor	2.62B	26.00	-7.90	-4.26%	-156.36%	-68.97%	0.16
OROR Royalties Inc.Direct Competitor	7.26B	38.74	34.90	47.52%	74.29%	14.1%	0.01
WPMWheaton Precious Metals Corp.Direct Competitor	61.1B	134.57	40.90	83.33%	63.59%	18.53%	0.00
RGLDRoyal Gold, Inc.Direct Competitor	16.45B	236.88	35.41	44.57%	48.53%	11.85%	0.13
FNVFranco-Nevada CorporationDirect Competitor	45.21B	234.50	40.02	66.42%	61.07%	16.25%	0.00
XOMAXOMA Royalty Corp.Product Competitor	493.33M	41.60	28.49	83.06%	56.4%	31.88%	1.57
DRIDarden Restaurants, Inc.Product Competitor	23.17B	195.70	22.09	6.03%	8.66%	50.71%	2.70
EPDEnterprise Products Partners L.P.Product Competitor	81.2B	37.56	14.12	-6.44%	11.03%	19.29%	1.14

Compare RPRX vs Peers

Royalty Pharma plc (RPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RCUS

Most directly comparable listed peer for RPRX.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare RPRX against a more recognizable public peer.

Peer Set

Compare Top 5

vs RCUS, OR, WPM, RGLD

RPRX Income Statement

Royalty Pharma plc (RPRX) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	1.6B	1.79B	1.81B	2.12B	2.29B	2.24B	2.35B	2.26B	2.38B	2.44B
Revenue Growth %	-	12.33%	1.08%	16.98%	7.87%	-2.28%	5.24%	-3.86%	5.06%	7.82%
Cost of Goods Sold	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	1.6B▲ 0%	1.79B▲ 12.3%	1.81B▲ 1.1%	2.12B▲ 17.0%	2.29B▲ 7.9%	2.24B▼ 2.3%	2.35B▲ 5.2%	2.26B▼ 3.9%	2.38B▲ 5.1%	1.81B▲ 0%
Gross Margin %	100%	100%	100%	100%	100%	100%	100%	100%	100%	74.15%
Gross Profit Growth %	-	12.33%	1.08%	16.98%	7.87%	-2.28%	5.24%	-3.86%	5.06%	-
Operating Expenses	658.24M	430.45M	-808.92M	526.95M	858.75M	1.93B	862.4M	971.13M	818.67M	983.61M
OpEx % of Revenue	41.19%	23.98%	-44.59%	24.83%	37.51%	86.27%	36.63%	42.9%	34.42%	-
Selling, General & Admin	106.44M	61.91M	103.44M	181.72M	182.83M	227.3M	249.75M	236.67M	573.48M	621.77M
SG&A % of Revenue	6.66%	3.45%	5.7%	8.56%	7.99%	10.16%	10.61%	10.46%	24.11%	-
Research & Development	117.87M	392.61M	83.04M	26.29M	200.08M	177.11M	52M	2M	452M	442M
R&D % of Revenue	7.38%	21.87%	4.58%	1.24%	8.74%	7.92%	2.21%	0.09%	19.01%	-
Other Operating Expenses	433.93M	-24.07M	-995.4M	318.95M	475.84M	1.53B	560.66M	732.46M	-206.81M	1000K
Operating Income	939.69M▲ 0%	1.36B▲ 45.2%	2.62B▲ 92.3%	1.6B▼ 39.2%	1.43B▼ 10.3%	307.06M▼ 78.5%	1.49B▲ 385.9%	1.29B▼ 13.4%	1.56B▲ 20.7%	1.59B▲ 0%
Operating Margin %	58.81%	76.02%	144.59%	75.17%	62.49%	13.73%	63.37%	57.1%	65.58%	65.07%
Operating Income Growth %	-	45.2%	92.25%	-39.18%	-10.32%	-78.54%	385.94%	-13.38%	20.66%	-
EBITDA	972.96M	1.4B	2.65B	1.62B	1.45B	312.74M	1.89B	1.56B	1.56B	1.54B
EBITDA Margin %	60.89%	77.87%	145.91%	76.26%	63.5%	13.98%	80.15%	68.76%	65.74%	63.1%
EBITDA Growth %	-	43.66%	89.39%	-38.86%	-10.18%	-78.49%	503.47%	-17.54%	0.45%	-23.56%
D&A (Non-Cash Add-back)	33.27M	33.27M	23.92M	23.06M	23M	5.67M	0	0	3.85M	2.47M
EBIT	1.59B	1.8B	2.73B	1.86B	1.41B	418.02M	1.89B	1.56B	1.63B	1.13B
Net Interest Income	-240.58M	-255.51M	-246.24M	-128.68M	-112.61M	-109.63M	-114.9M	-178.17M	-274.07M	-220.1M
Interest Income	6.76M	24.44M	22.33M	28.38M	53.53M	78.33M	72.29M	47.34M	33.59M	22.3M
Interest Expense	247.34M	279.96M	268.57M	157.06M	166.14M	187.96M	187.19M	225.51M	307.66M	336.4M
Other Income/Expense	403.49M	153.41M	-161.76M	106.56M	-189.51M	-77M	207.94M	38.37M	-235.33M	-229.58M
Pretax Income	1.34B▲ 0%	1.52B▲ 13.0%	2.46B▲ 62.2%	1.7B▼ 30.9%	1.24B▼ 27.1%	230.06M▼ 81.5%	1.7B▲ 639.0%	1.33B▼ 21.7%	1.32B▼ 0.5%	1.36B▲ 0%
Pretax Margin %	84.06%	84.57%	135.67%	80.19%	54.21%	10.28%	72.2%	58.79%	55.68%	55.67%
Income Tax	0	0	0	0	0	0	0	0	0	173M
Effective Tax Rate %	0%	0%	0%	0%	0%	0%	0%	0%	0%	12.73%
Net Income	1.21B▲ 0%	1.38B▲ 13.9%	2.35B▲ 70.5%	975.04M▼ 58.5%	619.73M▼ 36.4%	42.83M▼ 93.1%	1.13B▲ 2549.5%	858.98M▼ 24.3%	770.95M▼ 10.2%	827.6M▲ 0%
Net Margin %	75.72%	76.76%	129.45%	45.94%	27.07%	1.91%	48.2%	37.95%	32.42%	33.9%
Net Income Growth %	-	13.86%	70.46%	-58.48%	-36.44%	-93.09%	2549.5%	-24.31%	-10.25%	-24.25%
Net Income (Continuing)	1.34B	1.52B	2.46B	1.7B	1.24B	230.06M	1.7B	1.33B	1.32B	890.76M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	63.87M	35.88M	5.08B	4.47B	3.9B	3.56B	3.4B	3.24B	87.42M
EPS (Diluted)	3.42▲ 0%	3.89▲ 13.7%	6.63▲ 70.4%	1.28▼ 80.7%	1.49▲ 16.4%	0.10▼ 93.3%	2.53▲ 2430.0%	1.45▼ 42.7%	1.80▲ 24.1%	-▲ 0%
EPS Growth %	-	13.74%	70.44%	-80.69%	16.41%	-93.29%	2430%	-42.69%	24.14%	-42.86%
EPS (Basic)	3.42	3.89	6.63	1.28	1.49	0.10	3.41	1.93	2.33	-
Diluted Shares Outstanding	354.18M	354.18M	354.18M	388.13M	414.8M	437.97M	602.9M	594M	559.61M	0
Basic Shares Outstanding	354.18M	354.18M	354.18M	388.13M	414.79M	437.96M	447.6M	445.99M	431.89M	0
Dividend Payout Ratio	60.76%	59.11%	31.48%	40.8%	46.02%	778.21%	31.58%	43.83%	49.06%	-

RPRX Balance Sheet

Royalty Pharma plc (RPRX) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	2.95B	2.61B	832.07M	2.7B	2.88B	2.55B	1.27B	1.8B	619M	586M
Cash & Short-Term Investments	1.38B	2.39B	793.21M	2.65B	2.8B	2.43B	1.23B	1.77B	637.5M	586M
Cash Only	1.38B	1.92B	246.2M	1.01B	1.54B	1.71B	477.01M	929.03M	618.7M	586M
Short-Term Investments	0	461.82M	547.01M	1.64B	1.26B	717.04M	756.74M	841.97M	18.8M	21.9M
Accounts Receivable	0	198.63M	38.77M	39.17M	68.31M	36.6M	22.41M	26.96M	883.7M	0
Days Sales Outstanding	-	40.39	7.8	6.74	10.89	5.97	3.47	4.35	135.63	67.31
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	1.57B	23.89M	92K	8.6M	6.63M	90.52M	18.04M	4.19M	-902.2M	0
Total Non-Current Assets	8.43B	8.76B	11.62B	13.32B	14.64B	14.26B	15.11B	16.42B	17.06B	17.32B
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	493.12x
Goodwill	0	0	0	0	0	0	0	0	924.63M	924.63M
Intangible Assets	0	75.65M	51.72M	28.67M	5.67M	0	0	15.13B	0	0
Long-Term Investments	0	8.67B	11.48B	13.28B	14.63B	14.23B	15.1B	16.39B	171.31M	17.57B
Other Non-Current Assets	0	19.11M	87.95M	10M	4.14M	29.63M	6.52M	-15.09B	15.97B	47.39B
Total Assets	11.37B▲ 0%	11.37B▼ 0.0%	12.45B▲ 9.5%	16.02B▲ 28.7%	17.52B▲ 9.3%	16.81B▼ 4.0%	16.38B▼ 2.6%	18.22B▲ 11.2%	19.62B▲ 7.7%	19.82B▲ 0%
Asset Turnover	0.14x	0.16x	0.15x	0.13x	0.13x	0.13x	0.14x	0.12x	0.12x	0.13x
Asset Growth %	-	-0.03%	9.5%	28.68%	9.34%	-4.01%	-2.57%	11.24%	7.67%	31.21%
Total Current Liabilities	383.41M	580.17M	333.42M	307.89M	171.25M	1.17B	161.38M	1.25B	636.21M	535.68M
Accounts Payable	0	4.48M	11.18M	10.78M	5.62M	7.91M	15.16M	13.37M	19.4M	0
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	280.93M	281.44M	281.98M	0	0	997.51M	0	997.77M	380M	380M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	102.48M	0	9.21M	18.6M	0	12.4M	11.38M	68.6M	163.98M	155.68M
Current Ratio	7.69x	4.50x	2.50x	8.76x	16.81x	2.19x	7.90x	1.44x	0.97x	0.97x
Quick Ratio	7.69x	4.50x	2.50x	8.76x	16.81x	2.19x	7.90x	1.44x	0.97x	0.97x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	67.31
Total Non-Current Liabilities	6.52B	6.24B	5.98B	5.82B	7.1B	6.12B	6.14B	6.63B	9.27B	9.34B
Long-Term Debt	6.52B	6.24B	5.96B	5.82B	7.1B	6.12B	6.14B	6.61B	8.57B	8.58B
Capital Lease Obligations	0	0	0	0	0	0	0	0	16.1M	33M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	18.9M	0	0	2.5M	900K	12.08M	682.61M	2.67B
Total Liabilities	6.9B	6.82B	6.31B	6.12B	7.27B	7.29B	6.3B	7.88B	9.91B	9.88B
Total Debt	6.8B	6.52B	6.24B	5.82B	7.1B	7.12B	6.14B	7.61B	8.95B	8.96B
Net Debt	5.42B	4.6B	5.99B	4.81B	5.56B	5.41B	5.66B	6.68B	8.33B	-586M
Debt / Equity	1.52x	1.43x	1.02x	0.59x	0.69x	0.75x	0.61x	0.74x	0.92x	0.92x
Debt / EBITDA	6.99x	4.66x	2.36x	3.59x	4.88x	22.76x	3.25x	4.89x	5.73x	5.81x
Net Debt / EBITDA	5.57x	3.29x	2.26x	2.97x	3.82x	17.28x	3.00x	4.29x	5.33x	5.33x
Interest Coverage	6.43x	6.42x	10.16x	11.84x	8.47x	2.22x	10.08x	6.90x	5.30x	3.37x
Total Equity	4.46B▲ 0%	4.55B▲ 2.1%	6.14B▲ 34.9%	9.9B▲ 61.1%	10.25B▲ 3.6%	9.53B▼ 7.1%	10.08B▲ 5.9%	10.34B▲ 2.6%	9.71B▼ 6.1%	9.94B▲ 0%
Equity Growth %	-	2.05%	34.91%	61.13%	3.56%	-7.06%	5.87%	2.56%	-6.07%	-13.32%
Book Value per Share	12.59	12.85	17.34	25.50	24.71	21.75	16.73	17.41	17.36	74.96
Total Shareholders' Equity	4.46B	4.49B	6.11B	4.82B	5.78B	5.63B	6.53B	6.95B	6.48B	9.94B
Common Stock	0	3.28B	3.28B	102K	106K	107K	108K	108K	106K	45K
Retained Earnings	0	1.22B	2.83B	1.92B	2.26B	1.96B	2.52B	2.85B	2.36B	2.51B
Treasury Stock	0	0	-4.27M	-2.32M	-2.71M	-2.81M	-2.63M	-2.66M	-2.61M	0
Accumulated OCI	0	-10.26M	2.09M	34.4M	16.49M	0	0	0	0	0
Minority Interest	0	63.87M	35.88M	5.08B	4.47B	3.9B	3.56B	3.4B	3.24B	87.42M

RPRX Cash Flow Statement

Royalty Pharma plc (RPRX) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	1.42B	1.62B	1.67B	2.03B	2.02B	2.14B	2.99B	2.77B	2.49B	2.49B
Operating CF Margin %	88.76%	90.16%	91.9%	95.87%	88.12%	95.83%	126.89%	122.33%	104.69%	-
Operating CF Growth %	-	14.1%	3.02%	22.04%	-0.84%	6.27%	39.36%	-7.32%	-10.08%	-12.99%
Net Income	1.34B	1.52B	2.46B	1.7B	1.24B	230.06M	1.7B	1.33B	1.32B	827.6M
Depreciation & Amortization	33.27M	33.27M	23.92M	23.06M	23M	5.67M	0	0	3.85M	2.47M
Stock-Based Compensation	0	0	0	5.43M	2.44M	2.17M	2.36M	2.34M	289.89M	289.38M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	1.52B	1.63B	-793.43M	228.22M	767.22M	1.87B	1.28B	1.38B	889.04M	1.38B
Working Capital Changes	-1.48B	-1.56B	-24.67M	75.97M	-16.32M	32.66M	5.38M	53.38M	-17.15M	47.33M
Change in Receivables	-84.48M	111.53M	159.86M	-400K	-29.14M	-4.74M	-1.52M	-4.55M	-2.36M	-5.53M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	1.35M	6.5M	-766K	-4.59M	2.29M	6.24M	-2.29M	-13.93M	-24.01M
Cash from Investing	-1.59B	303.42M	-2.15B	-2.76B	-1.87B	-1.03B	-2.07B	-2.68B	-1.61B	-2.6B
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-2M	-24.17M	-27.04M	-40.16M	-34.85M	-9.9M	-12.54M	-10.96M	-74.42M	-74.42M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	115M	0	-250M	15.08M	-18.08M	0	29.44M	-49.32M	-175.11M	-620.37M
Cash from Financing	-123.25M	-1.38B	-1.19B	1.49B	385.11M	-944.86M	-2.15B	361.14M	-1.19B	-517.67M
Debt Issued (Net)	907M	-294M	-294M	680.63M	1.27B	0	-1B	1.47B	954.48M	954.48M
Equity Issued (Net)	0	0	-4.27M	1.91B	0	0	-304.76M	-229.65M	-1.23B	-518.6M
Dividends Paid	-735.17M	-814.36M	-739.28M	-397.84M	-285.18M	-333.32M	-358.33M	-376.46M	-378.25M	-386.9M
Share Repurchases	0	0	-4.27M	0	0	0	-304.76M	-229.65M	-1.23B	-518.6M
Other Financing	-295.08M	-270.74M	-154.08M	-704.36M	-602.24M	-611.53M	-485.67M	-503.97M	-534.81M	-566.65M
Net Change in Cash	-292.65M▲ 0%	542.64M▲ 285.4%	-1.68B▼ 409.2%	762.48M▲ 145.4%	532.37M▼ 30.2%	169.7M▼ 68.1%	-1.23B▼ 827.0%	452.02M▲ 136.6%	-310.33M▼ 168.7%	-502.02M▲ 0%
Free Cash Flow	1.42B▲ 0%	1.62B▲ 14.1%	1.67B▲ 3.0%	2.03B▲ 22.0%	2.02B▼ 0.8%	2.14B▲ 6.3%	2.99B▲ 39.4%	2.77B▼ 7.3%	2.49B▼ 10.1%	2.61B▲ 0%
FCF Margin %	88.76%	90.16%	91.9%	95.87%	88.12%	95.83%	126.89%	122.33%	104.69%	107%
FCF Growth %	-	14.1%	3.02%	22.04%	-0.84%	6.27%	39.36%	-7.32%	-10.08%	-3.28%
FCF per Share	4.00	4.57	4.71	5.24	4.86	4.90	4.96	4.66	4.45	4.45
FCF Conversion (FCF/Net Income)	1.17x	1.17x	0.71x	2.09x	3.26x	50.06x	2.63x	3.22x	3.23x	3.16x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

RPRX Key Ratios

Royalty Pharma plc (RPRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	30.57%	43.92%	12.16%	6.15%	0.43%	11.57%	8.41%	7.69%	8.54%
Return on Invested Capital (ROIC)	10.76%	18.49%	8.92%	7.03%	1.5%	7.3%	5.92%	6.67%	6.67%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	74.15%
Net Margin	76.76%	129.45%	45.94%	27.07%	1.91%	48.2%	37.95%	32.42%	33.9%
Debt / Equity	1.43x	1.02x	0.59x	0.69x	0.75x	0.61x	0.74x	0.92x	0.92x
Interest Coverage	6.42x	10.16x	11.84x	8.47x	2.22x	10.08x	6.90x	5.30x	3.37x
FCF Conversion	1.17x	0.71x	2.09x	3.26x	50.06x	2.63x	3.22x	3.23x	3.16x
Revenue Growth	12.33%	1.08%	16.98%	7.87%	-2.28%	5.24%	-3.86%	5.06%	7.82%

RPRX SEC Filings & Documents

Royalty Pharma plc (RPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 6, 2026·SEC

Material company update

Apr 13, 2026·SEC

Material company update

Feb 11, 2026·SEC

10-K Annual Reports

FY 2026

Feb 11, 2026·SEC

FY 2025

Feb 12, 2025·SEC

FY 2024

Feb 15, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 6, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

RPRX Frequently Asked Questions

Royalty Pharma plc (RPRX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Royalty Pharma plc (RPRX) reported $2.44B in revenue for fiscal year 2025. This represents a 53% increase from $1.60B in 2017.

Royalty Pharma plc (RPRX) grew revenue by 5.1% over the past year. This is steady growth.

Yes, Royalty Pharma plc (RPRX) is profitable, generating $827.6M in net income for fiscal year 2025 (32.4% net margin).

Dividend & Returns

Yes, Royalty Pharma plc (RPRX) pays a dividend with a yield of 1.33%. This makes it attractive for income-focused investors.

Royalty Pharma plc (RPRX) has a return on equity (ROE) of 7.7%. This is below average, suggesting room for improvement.

Royalty Pharma plc (RPRX) generated $2.61B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More RPRX

Royalty Pharma plc (RPRX) financial analysis — history, returns, DCA and operating performance tools

Full RPRX Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Royalty Pharma plc(RPRX)Earnings, Financials & Key Ratios

RPRX Key Insights

✓Strengths

✗Weaknesses

RPRX Price & Volume

RPRX Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

RPRX Recent Earnings

RPRX Peer Comparison

Compare RPRX vs Peers

vs RCUS

vs JNJ

Compare Top 5

RPRX Income Statement

RPRX Balance Sheet

RPRX Cash Flow Statement

RPRX Key Ratios

RPRX SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

RPRX Frequently Asked Questions

Explore More RPRX

Full RPRX Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation